More connectivity and flexibility are offered by the fifth FDA clearance in less than two years, enhancing the experience for patients and providers.

Improved internet connectivity capabilities, particularly for NeuroStar providers with restricted networks, were announced by Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company devoted to designing, developing, and marketing products that improve the quality of life for patients suffering from neurohealth disorders.

According to Cory Anderson, SVP of R&D and Clinical, by including Wi-Fi functionality into the NeuroStar system, providers now have more freedom in where they install their NeuroStar system and have access to more connectivity options for TrakStar. “This most recent development illustrates our ongoing dedication to making technology investments that improve access to TrakStar information and streamline practice operations.

The 3.7 platform gives NeuroStar providers access to all the capabilities and advantages that were previously available only to TrakStar cloud customers while maintaining HIPAA compliance and patient protection. This feature also makes it possible to collect data from other practices, which improves our capacity to learn from a wider range of practices.

“The NeuroStar system’s new Wi-Fi capability is an interesting addition,” said Dr. Kenneth Pages, TMS of South Tampa. It streamlines daily operations and enables my practice to focus entirely on providing the greatest care for patients.

In addition to a new teaching initiative called “Get There FASTER with TrakStar” targeted towards NeuroStar providers, Neuronetics has launched the first of several software updates for the TrakStar® Patient Data Management System this year. Visit neurostar.com for more details about NeuroStar.

On neuronetics:
Mental and physical wellness are both crucial, according to Neuronetics, Inc. With its NeuroStar Advanced Treatment for Mental Health, Neuronetics, a leader in neuroscience, is redefining what patients and doctors can anticipate. When a conventional medication hasn’t helped, neurohealth issues can be treated with NeuroStar, a non-drug, non-invasive procedure that can help patients live better lives. Adults with major depressive disorder (MDD), adults with obsessive-compulsive disorder (OCD), and adult patients with MDD who may also have comorbid anxiety symptoms are all eligible to use NeuroStar, which has received FDA clearance for these uses (anxious depression).With more than 5.3 million treatments administered, NeuroStar Advanced Treatment is the most popular transcranial magnetic stimulation (TMS) therapy for individuals with MDD. The world’s largest depression Outcomes Registry and the largest clinical data set of any TMS technology for depression support NeuroStar. The mission of Neuronetics is to alter lives by providing a treatment that is outstanding and gets amazing outcomes. www.neurostar.com provides information about prescribing and safety.